Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Iron Overload Clinical Trial

Official title:

Identification of Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients Undergoing a Hematopoietic Stem Cell Transplant (HSCT)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04423237
• Other study ID #: 1105/2015
• Status: Recruiting
• Start date: September 30, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: October 2023
• Source: University of Pisa
• Contact: Natalia Maximova, MD
• Phone: +39.040.3785.565
• Email: natalia.maximova[@]burlo.trieste.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hematopoietic Stem Cell Transplantation (HSCT) is currently a standard procedure for a wide range of blood-oncological diseases and genetic disorders. Recent improvements in transplant technologies, infection prevention and graft-versus-host-disease (GVHD) management procedures have significantly reduced the transplant-related mortality (TRM). However, approximately 50% of pediatric patients may develop liver dysfunction before HSCT and 74% to 85.5% after HSCT, with a TRM related to liver dysfunction reaching 46%. The liver and pancreas complications still remain too high for the difficulties and diagnostic inefficiencies and, consequently, for the lack of targeted and safer therapies. The diagnostic problems can be summarized in 3 major points: a) the histological examination of liver and pancreas parenchyma cannot be routinely performed because of the organ anatomy and the relative risk of the bioptic procedures; b) the lack of specific biomarkers or advanced imaging techniques appropriate for the diagnosis of HSCT complications; c) the multifactorial causes of organ complications, as well as drug toxicities, GVHD, siderosis, ductopenia (considered as an index of hepatic GVHD), the accumulation of potentially toxic substances favored by siderosis and ductopenia. In more than 50% of HSCT patients, siderosis and/or ductopenia may represent common pathological conditions. Furthermore, international guidelines issued by onco-hematology and transplantation scientific societies recommend a chelating treatment with deferasirox in all hematological and oncological patients undergoing an intense transfusion regimen. However, in the presence of siderosis and marked ductopenia, patients receiving deferasirox may experience both severe renal and hematological toxicities and lack of effectiveness of the chelating treatment.

Therefore, the principal aim of the present retrospective study will be the evaluation of the transplant-related mortality (TRM) in patients requiring a chelation treatment according to the Italian guidelines in pediatric patients

Description:

The present retrospective study will be conducted at the Bone Marrow Transplant Center, IRCCS Burlo Garofolo, Trieste, Italy. All pediatric patients who underwent one or more allogeneic HSCTs between 2010 and 2018 will be enrolled according to inclusion/exclusion criteria.

The following data will be collected in a retrospective manner:

• Data on the underlying disease (diagnosis, therapeutic protocol, transfusion regimen, possible relapses, type of transplant, conditioning regimen, infectious complications, immunosuppressive treatment, including use of steroids);

• Pre-transplant liver and pancreatic function, as well as quantification of iron content by nuclear magnetic resonance (MRI);

• Pre-transplant histological evaluation of liver parenchyma in case of pre-existing liver disease;

• Post-transplant liver and pancreatic function and the evaluation of parenchymal accumulation of Fe+;

• Length and doses of DFX treatment, and corresponding drug plasma concentrations as per routine drug monitoring protocols;

• Treatment tolerability according to CTC-AE grading V5.0, November 27, 2017 The post-transplant data will be collected within 2 years from HSCT (or the last HSCT when more than one).

The data entered in an appropriate anonymous database will be processed by descriptive statistics and uni- multivariate statistical analyses according to study endpoints. DFX plasma concentrations will be analyzed by means of to a nonlinear mixed effect modeling approach to elaborate a population pharmacokinetic (POP/PK) model. POP/PK findings will be further analyzed together with clinical and laboratory data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: December 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion Criteria:

• one or more allogeneic HSCT

• any type of disease (blood-oncological or genetic), from any type of donor (sibling, MUD, haploidentical) and with any source of stem cells (spinal cord, peripheral blood stem cells, cord blood)

• diagnosis of moderate-to-severe siderosis (by nuclear magnetic resonance imaging, MRI) and who needed a chelation treatment with deferasirox

• one or more liver biopsies in the post-transplant period to perform histological examinations

• Complete results from lab analyses

• 2-year follow-up after HSCT

• therapeutic drug monitoring (TDM) protocol for deferasirox plasma concentration as per clinical routine

• Sign of the informed consent by the parents or legal representatives

Exclusion Criteria:

• Lack of liver biopsies after transplantation, results from laboratory analyses or TDM or MRI

• Lack of informed consent

Related Conditions & MeSH terms

• Iron Overload

Intervention

Drug:
• Deferasirox
DEFERASIROX administered as per clinical practice and according to technical note

Locations

Country	Name	City	State
Italy	IRCCS Burlo Garofolo	Trieste

Sponsors (3)

Lead Sponsor	Collaborator
University of Pisa	IRCCS Burlo Garofolo, University of Genova

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Galeotti L, Ceccherini F, Fucile C, Marini V, Di Paolo A, Maximova N, Mattioli F. Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients. Pharmaceutics. 2021 Aug 11;13(8):1238. doi: 10.3390/pharmaceutics13081238. — View Citation

Maximova N, Zanon D, Pascolo L, Zennaro F, Gregori M, Grosso D, Sonzogni A. Metal accumulation in the renal cortex of a pediatric patient with sickle cell disease: a case report and review of the literature. J Pediatr Hematol Oncol. 2015 May;37(4):311-4. doi: 10.1097/MPH.0000000000000322. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transplant-related mortality (TRM)	TRM in SIO/SIO+D patients treated with deferasirox as per Italian guidelines	0-24 months after transplant
Secondary	Post-HSCT liver and pancreatic complications	Incidence of post-HSCT liver and pancreatic complications in SIO/SIO+D patients treated with deferasirox as per Italian guidelines	0-24 months after transplant
Secondary	Time to iron concentration normalization	The times required for the normalization of the Iron Concentration in SIO and SIO+D patients	0-24 months after transplant
Secondary	Statistical analysis of risk factors for ductopenia	The correlation between ductopenia and potential risk factors will be investigated by uni- and multi-variate analyses. The following data will be included in the analyses as potential risk factors: chemo-radiotherapy regimens prior to HSCT (drugs and doses), number of blood transfusions	0-24 months after transplant
Secondary	Minimum plasma concentrations of deferasirox	In SIO/SIO+D patients, a factorial analysis for mixed data and a nonlinear mixed effect modeling approach will be used to investigate plasma pharmacokinetics of deferasirox in terms of patients' exposure (minimum plasma concentration, Cmin) and to evaluate the effect of identified covariates on drug disposition.	0-24 months after transplant
Secondary	Correlation of minimum plasma concentrations of deferasirox with drug tolerability	In SIO/SIO+D patients, uni- and multi-variate analyses will be adopted to assess the correlation of Cmin with treatment tolerability	0-24 months after transplant